Bipolar disorders (BD) represent a severe leading disabling mental condition worldwide
characterized by episodic and often progressive mood fluctuations with manic and …

A number of effective maintenance medication options exist for bipolar disorder (BD) and
these are regarded as the foundation of long-term treatment in BD. However, nonadherence …

Bipolar disorder is heterogeneous in phenomenology, illness trajectory, and response to
treatment. Despite evidence for the efficacy of multimodality interventions, the majority of …

Objective: We reviewed important clinical aspects of bipolar depression, a progressive
psychiatric condition that is commonly treated in primary care. Bipolar depression is …

The leading guide to group-based cognitive-behavioral therapy (CBT) has now been
significantly revised with 70% new material, reflecting over 15 years of research and clinical …

Bipolar depression (BD-D) is both common and incredibly challenging to treat. Even treated
individuals with BD-D experience depression approximately 19% of the time, and …

Background Schizophrenia and bipolar disorder are characterized by a high disease
burden. Antipsychotic medication is an essential part of the treatment. However, non …

Background: Medication non-adherence has a dynamic, temporal and multifactorial nature
with a significant impact on economic and clinical outcomes. Interventions to improve …

A person's beliefs about their chronic condition (illness representations) influence health
and treatment outcomes. Recently, researchers have used clustering approaches to identify …

Objective Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting
injectable antipsychotic formulation for administration every 2 months. A 32-week trial …